Effects of structure on inhibitory activity in a series of mechanism-based inhibitors of human neutrophil elastase

Enantioselective aza-Friedel–Crafts reaction of cyclic ketimines with indoles using chiral imidazoline–phosphoric acid catalysts

A highly enantioselective aza-Friedel Crafts reaction of cyclic 4-aryl-3-oxo-1,2,5-thiadiazol-1,1-oxides as cyclic ketimines with indoles was developed.

Diastereo- and enantioselective Mannich/cyclization cascade reaction of isocyanoacetates with cyclic sulfamide ketimines by cinchona alkaloid squaramide/AgOAc cooperative catalysis

This reaction provides facile access to a variety of optically active imidazoline-fused sulfahydantoin derivatives in excellent yields and good to excellent stereoselectivities.

Neutrophil elastase inhibitors: recent advances in the development of mechanism-based and nonelectrophilic inhibitors

Due to its implication in pathologies of prevalent diseases such as chronic obstructive pulmonary disease, fibrosis, bronchiectasis and ARDS, the serine protease, human neutrophil elastase, has been in focus for drug-development efforts over the last two decades. In recent years, continued efforts to identify and optimize novel mechanism-based inhibitors have led to a number of new inhibitors being reported. These compounds show promising potency and selectivity profiles, although their use is still limited by their inherent stability. Recently, two novel classes of potent and selective, synthetic, nonelectrophilic human neutrophil elastase inhibitors that display improved stability and overall drug-like properties have been reported. The most advanced compound from these classes, AZD9668, has been reported to show significant effects on relevant biomarkers in bronchiectasis and cystic fibrosis patient populations.